Aseptic and terminal sterilized manufacture of injectable vials, pre-filled syringes, and oral liquids is the area of expertise for Innoxel Lifesciences, which has its headquarters located in Vadodara, India. Specializing in proprietary drug-delivery formulations for specific therapies including oncology and critical care, we are a full-service pharmaceutical company with manufacturing and research and development capabilities. To strengthen India's growing worldwide market presence by guaranteeing unrivaled quality standards, our main focus is on regulated markets like the USA.
Having been founded in 2020, Innoxel Lifesciences is a distinctive greenfield location. We have followed US FDA, UK MHRA, and EU GMP guidelines at every step of the careful planning, building, and operation. Q1 2024 will see the submission of the first batch of ANDAs via Innoxel to the US FDA, paving the way for a possible inspection by the agency in early 2025.